Literature DB >> 20171785

Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1.

Hongyan Zhu1, Melissa K Mingler, Melissa L McBride, Andrew J Murphy, David M Valenzuela, George D Yancopoulos, Michael T Williams, Charles V Vorhees, Marc E Rothenberg.   

Abstract

NPSR1 is a G protein coupled receptor expressed in multiple brain regions involved in modulation of stress. Central administration of NPS, the putative endogenous ligand of NPSR1, can induce hyperlocomotion, anxiolytic effects and activation of the HPA axis. The role of NPSR1 in the brain remains unsettled. Here we used NPSR1 gene-targeted mice to define the functional role of NPSR1 under basal conditions on locomotion, anxiety- and/or depression-like behavior, corticosterone levels, acoustic startle with prepulse inhibition, learning and memory, and under NPS-induced locomotor activation, anxiolysis, and corticosterone release. Male, but not female, NPSR1-deficient mice exhibited enhanced depression-like behavior in a forced swim test, reduced acoustic startle response, and minor changes in the Morris water maze. Neither male nor female NPSR1-deficient mice showed alterations of baseline locomotion, anxiety-like behavior, or corticosterone release after exposure to a forced swim test or methamphetamine challenge in an open-field. After intracerebroventricular (ICV) administration of NPS, NPSR1-deficient mice failed to show normal NPS-induced increases in locomotion, anxiolysis, or corticosterone release compared with WT NPS-treated mice. These findings demonstrate that NPSR1 is essential in mediating NPS effects on behavior. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20171785      PMCID: PMC2888805          DOI: 10.1016/j.psyneuen.2010.01.012

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  41 in total

1.  Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7.

Authors:  John F Cryan; Peter H Kelly; Hans C Neijt; Gilles Sansig; Peter J Flor; Herman van Der Putten
Journal:  Eur J Neurosci       Date:  2003-06       Impact factor: 3.386

2.  Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I.

Authors:  Virginie Bernier; Rino Stocco; Michael J Bogusky; Joseph G Joyce; Christine Parachoniak; Karl Grenier; Michael Arget; Marie-Claude Mathieu; Gary P O'Neill; Deborah Slipetz; Michael A Crackower; Christopher M Tan; Alex G Therien
Journal:  J Biol Chem       Date:  2006-06-20       Impact factor: 5.157

3.  Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.

Authors:  Naoe Okamura; Stephen A Habay; Joanne Zeng; A Richard Chamberlin; Rainer K Reinscheid
Journal:  J Pharmacol Exp Ther       Date:  2008-03-12       Impact factor: 4.030

4.  Genomewide survey of panic disorder.

Authors:  R R Crowe; R Goedken; S Samuelson; R Wilson; J Nelson; R Noyes
Journal:  Am J Med Genet       Date:  2001-01-08

5.  Characterization of GPRA, a novel G protein-coupled receptor related to asthma.

Authors:  Johanna Vendelin; Ville Pulkkinen; Marko Rehn; Asta Pirskanen; Anne Räisänen-Sokolowski; Annika Laitinen; Lauri A Laitinen; Juha Kere; Tarja Laitinen
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06-09       Impact factor: 6.914

6.  Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain.

Authors:  Yan-Ling Xu; Christine M Gall; Valerie R Jackson; Olivier Civelli; Rainer K Reinscheid
Journal:  J Comp Neurol       Date:  2007-01-01       Impact factor: 3.215

Review 7.  Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome.

Authors:  Javier Santos; Carmen Alonso; María Vicario; Laura Ramos; Beatriz Lobo; J-Ramón Malagelada
Journal:  Curr Mol Med       Date:  2008-06       Impact factor: 2.222

8.  Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder.

Authors:  Naoe Okamura; Kenji Hashimoto; Masaomi Iyo; Eiji Shimizu; Astrid Dempfle; Susann Friedel; Rainer K Reinscheid
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-07-03       Impact factor: 5.067

9.  Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice.

Authors:  A Rizzi; R Vergura; G Marzola; C Ruzza; R Guerrini; S Salvadori; D Regoli; G Calo
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

10.  What is the Most Sensitive Measure of Water Maze Probe Test Performance?

Authors:  Hamid R Maei; Kirill Zaslavsky; Cátia M Teixeira; Paul W Frankland
Journal:  Front Integr Neurosci       Date:  2009-03-09
View more
  23 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

2.  Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons.

Authors:  Irina A Ionescu; Julien Dine; Yi-Chun Yen; Dominik R Buell; Leonie Herrmann; Florian Holsboer; Matthias Eder; Rainer Landgraf; Ulrike Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

3.  Sex differences in activation of the hypothalamic-pituitary-adrenal axis by methamphetamine.

Authors:  Damian G Zuloaga; Lance A Johnson; Maayan Agam; Jacob Raber
Journal:  J Neurochem       Date:  2014-02-10       Impact factor: 5.372

4.  Chronic ethanol potentiates the effect of neuropeptide s in the basolateral amygdala and shows increased anxiolytic and anti-depressive effects.

Authors:  Johan Enquist; Madeline Ferwerda; Anuradha Madhavan; Derek Hok; Jennifer L Whistler
Journal:  Neuropsychopharmacology       Date:  2012-06-27       Impact factor: 7.853

5.  Modification of caffeine effects on the affect-modulated startle by neuropeptide S receptor gene variation.

Authors:  Katharina Domschke; Benedikt Klauke; Bernward Winter; Agnes Gajewska; Martin J Herrmann; Bodo Warrings; Andreas Mühlberger; Katherina Wosnitza; Andrea Dlugos; Swantje Naunin; Kathrin Nienhaus; Manfred Fobker; Christian Jacob; Volker Arolt; Paul Pauli; Andreas Reif; Peter Zwanzger; Jürgen Deckert
Journal:  Psychopharmacology (Berl)       Date:  2012-03-08       Impact factor: 4.530

6.  The role of neuropeptide S and neuropeptide S receptor 1 in regulation of respiratory function in mice.

Authors:  Hongyan Zhu; Charles Perkins; Melissa K Mingler; Fred D Finkelman; Marc E Rothenberg
Journal:  Peptides       Date:  2010-12-16       Impact factor: 3.750

Review 7.  The genetics of anxiety-related negative valence system traits.

Authors:  Jeanne E Savage; Chelsea Sawyers; Roxann Roberson-Nay; John M Hettema
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-05-19       Impact factor: 3.568

8.  Developmental methamphetamine exposure results in short- and long-term alterations in hypothalamic-pituitary-adrenal-axis-associated proteins.

Authors:  Damian G Zuloaga; Jessica A Siegel; Summer F Acevedo; Maayan Agam; Jacob Raber
Journal:  Dev Neurosci       Date:  2013-07-11       Impact factor: 2.984

9.  Post-training gamma irradiation-enhanced contextual fear memory associated with reduced neuronal activation of the infralimbic cortex.

Authors:  Tara Kugelman; Damian G Zuloaga; Sydney Weber; Jacob Raber
Journal:  Behav Brain Res       Date:  2015-10-29       Impact factor: 3.332

10.  Immediate and lasting effects of chronic daily methamphetamine exposure on activation of cells in hypothalamic-pituitary-adrenal axis-associated brain regions.

Authors:  Damian G Zuloaga; Lance A Johnson; Sydney Weber; Jacob Raber
Journal:  Psychopharmacology (Berl)       Date:  2015-11-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.